72
Participants
Start Date
July 6, 2018
Primary Completion Date
December 13, 2022
Study Completion Date
December 13, 2022
DHP107
DHP107 200mg/m2 orally twice daily on Days 1, 8 and 15 every 28 days
IV Paclitaxel
IV Paclitaxel 80 mg/m2 QW (3 weeks on/1 week off)
University of Pittsburgh Medical Center (UPMC), Pittsburgh
Anne Arundel Health System Research Institute (AAHS), Annapolis
Boca Raton Regional Hospital (BRRH), Boca Raton
ASCLEPES Research Center(ARC), Weeki Wachee
Michigan Center of Medical Research(MCMR), Farmington Hills
Metro-Minnesota Community Oncology Research Consortium (MMCORC), Minneapolis
Saint Luke's Cancer Institute(SLCI), Kansas City
University of Kansas Medical Center(KUMC), Kansas City
Nevada Cancer Research Foundation (NCRF), Las Vegas
California Research Institute (CRI), Los Angeles
University of California San Francisco (UCSF), San Francisco
Massachusetts General Hospital(MGH), Boston
Onkologicka klinika, Fakultni nemocnice Olomouc (OUH), Olomouc
Onkologicky stacionar, NH Hospital a.s., nemocnice Horovice (NHH), Hořovice
Onkologicka klinika, Vseobecna fakultni nemocnice v Praze (VFN), Prague
Lead Sponsor
Daehwa Pharmaceutical Co., Ltd.
INDUSTRY